Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Equity Average (2020 - 2025)

Historic Equity Average for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $278.7 million.

  • Apellis Pharmaceuticals' Equity Average rose 1117.26% to $278.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.7 million, marking a year-over-year increase of 1117.26%. This contributed to the annual value of $211.5 million for FY2024, which is 1609.99% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Equity Average stood at $278.7 million for Q3 2025, which was up 1117.26% from $160.3 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Equity Average peaked at $378.8 million during Q2 2023, and registered a low of -$99.4 million during Q3 2021.
  • In the last 5 years, Apellis Pharmaceuticals' Equity Average had a median value of $230.6 million in 2024 and averaged $182.2 million.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 15883.86% in 2021, then soared by 223937.49% in 2023.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Equity Average stood at $70.7 million in 2021, then surged by 237.7% to $238.6 million in 2022, then dropped by 10.58% to $213.4 million in 2023, then grew by 9.11% to $232.8 million in 2024, then rose by 19.72% to $278.7 million in 2025.
  • Its last three reported values are $278.7 million in Q3 2025, $160.3 million for Q2 2025, and $196.4 million during Q1 2025.